Osteoarthritis - Pipeline Review, H1 2017

Published: Mar, 2017 | Pages: 270 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Osteoarthritis - Pipeline Review, H1 2017, provides an overview of the Osteoarthritis (Immunology) pipeline landscape.

Osteoarthritis (OA) is one of the most common forms of arthritis. It is a chronic condition in which the cartilage breaks down. Symptoms of osteoarthritis include sore or stiff joints, pain that is worse after activity, bone spurs and grating sensation. Risk factors include older age, joint injuries and obesity. Treatment includes surgery, medications like non-steroidal anti-inflammatory drugs (NSAIDs) and exercise.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Osteoarthritis - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Osteoarthritis (Immunology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Osteoarthritis (Immunology) pipeline guide also reviews of key players involved in therapeutic development for Osteoarthritis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 7, 21, 14, 46 and 14 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 5 and 5 molecules, respectively.

Osteoarthritis (Immunology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Osteoarthritis (Immunology).
- The pipeline guide reviews pipeline therapeutics for Osteoarthritis (Immunology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Osteoarthritis (Immunology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Osteoarthritis (Immunology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Osteoarthritis (Immunology)

Reasons To Buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Osteoarthritis (Immunology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Osteoarthritis (Immunology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

 Table of Contents

Table of Contents 2
List of Tables 7
List of Figures 9
Introduction 10
Global Markets Direct Report Coverage 10
Osteoarthritis - Overview 11
Osteoarthritis - Therapeutics Development 12
Pipeline Overview 12
Pipeline by Companies 13
Pipeline by Universities/Institutes 19
Products under Development by Companies 20
Products under Development by Universities/Institutes 26
Osteoarthritis - Therapeutics Assessment 27
Assessment by Target 27
Assessment by Mechanism of Action 30
Assessment by Route of Administration 33
Assessment by Molecule Type 35
Osteoarthritis - Companies Involved in Therapeutics Development 37
A. Menarini Industrie Farmaceutiche Riunite Srl 37
AbbVie Inc 37
Abiogen Pharma SpA 38
Ablynx NV 38
Achelios Therapeutics Inc 39
Addex Therapeutics Ltd 39
Amgen Inc 40
Amura Holdings Ltd 40
Arcarios BV 41
Asahi Kasei Pharma Corp 41
Asklepios BioPharmaceutical Inc 42
Astellas Pharma Inc 42
Biopharm GmbH 43
Bone Therapeutics SA 43
Can-Fite BioPharma Ltd 44
Cardax Inc 44
Cellular Biomedicine Group Inc 45
Cipla Ltd 45
Corestem Inc 46
Dong-A Socio Holdings Co Ltd 46
Evgen Pharma Plc 47
F. Hoffmann-La Roche Ltd 47
Galapagos NV 48
Gemphire Therapeutics Inc 48
GeneFrontier Corp 49
Genequine Biotherapeutics GmbH 49
GlaxoSmithKline Plc 50
HSRx Group 50
InKemia IUCT Group SA 51
International Stem Cell Corp 51
Jeil Pharmaceutical Co Ltd 52
Jenrin Discovery Inc 52
K-Stemcell Co Ltd 53
Kang Stem Biotech Co Ltd 53
Levolta Pharmaceuticals Inc 54
LG Chem, Ltd. 54
Marina Biotech Inc 55
Medivir AB 55
Merck KGaA 56
Mesoblast Ltd 56
Mor Research Application Ltd 57
NicOx SA 57
Nordic Bioscience A/S 58
Novartis AG 58
NovelMed Therapeutics Inc 59
Omeros Corp 59
Ono Pharmaceutical Co Ltd 60
OrthoCyte Corp 60
Osteologix Holdings Plc 61
Pfizer Inc 61
Pharmalink AB 62
Philogen SpA 62
PhytoHealth Corp 63
PLx Pharma Inc 63
ProteoThera Inc 64
Regeneus Ltd 64
Regulaxis SAS 65
Rottapharm Biotech Srl 65
Samumed LLC 66
Seikagaku Corp 66
Stelis Biopharma Pvt Ltd 67
Takeda Pharmaceutical Company Ltd 67
TissueGene Inc 68
Yooyoung Pharmaceutical Co Ltd 68
Yuhan Corp 69
Yungjin Pharm Co Ltd 69
Zimmer Biomet Holdings Inc 70
Osteoarthritis - Drug Profiles 71
(clodronate disodium + hyaluronic acid) - Drug Profile 71
(methylprednisolone + zoledronic acid) - Drug Profile 72
4-P004 - Drug Profile 74
ABT-981 - Drug Profile 75
ALLO-ASC - Drug Profile 76
AlloJoin - Drug Profile 78
AM-3701 - Drug Profile 79
AM-3876 - Drug Profile 80
Anatabine - Drug Profile 81
Antibody for Osteoarthritis - Drug Profile 84
Antibody to Inhibit TGF-Beta 1 for Osteoarthritis - Drug Profile 85
apocynin + paeonol - Drug Profile 86
ARC-118 - Drug Profile 87
AS-001 - Drug Profile 88
BNP-OA - Drug Profile 89
CDX-085 - Drug Profile 90
celecoxib - Drug Profile 93
Cell Therapy for Osteoarthritis - Drug Profile 94
Chondrostem - Drug Profile 95
clodronate disodium - Drug Profile 96
CMX-020 - Drug Profile 97
CR-8357 - Drug Profile 98
CRB-0017 - Drug Profile 99
CS-30MS02 - Drug Profile 100
DA-5202 - Drug Profile 101
denosumab - Drug Profile 102
DIS-BIO-EPS - Drug Profile 112
DNX-314 - Drug Profile 113
Drug for Bone Diseases and Osteoarthritis - Drug Profile 114
Drug for Osteoarthritis - Drug Profile 115
Drug for Osteoarthritis - Drug Profile 116
Drugs to Modulate Bone Morphogenetic Protein for Osteoarthritis and Fracture - Drug Profile 117
Drugs to Modulate PPAR-Delta for Metabolic and Musculoskeletal Disorders - Drug Profile 118
fasitibant chloride - Drug Profile 119
gemcabene calcium - Drug Profile 120
GFC-301 - Drug Profile 124
GLPG-1972 - Drug Profile 125
GQ-203 - Drug Profile 126
GQ-303 - Drug Profile 127
GSK-2394002 - Drug Profile 128
JD-4000 Series - Drug Profile 129
Jointstem - Drug Profile 130
JTA-004 - Drug Profile 132
Kartogenin - Drug Profile 133
KBP-056 - Drug Profile 134
ketoprofen - Drug Profile 135
LEVI-04 - Drug Profile 137
LH-021 - Drug Profile 138
LNA-043 - Drug Profile 139
MIV-711 - Drug Profile 140
Monoclonal Antibodies for Oncology, Inflammation and Osteoarthritis - Drug Profile 143
Monoclonal Antibody Conjugates for Osteoarthritis - Drug Profile 144
Monoclonal Antibody for Osteoarthritis - Drug Profile 145
MPC-75IA - Drug Profile 146
naproxcinod - Drug Profile 147
NBS-101 - Drug Profile 150
NStride APS - Drug Profile 152
ONO-4474 - Drug Profile 153
OTXCP-03 - Drug Profile 154
OTXCP-07 - Drug Profile 155
PF-152 - Drug Profile 156
PHDC-02 - Drug Profile 157
piclidenoson - Drug Profile 158
PL-1100 - Drug Profile 167
PN-6047 - Drug Profile 168
PRO-1 - Drug Profile 169
Progenza - Drug Profile 170
Protein for Osteoarthritis and Asthma - Drug Profile 172
Proteins for Rheumatoid Arthritis and Osteoarthritis - Drug Profile 173
PRX-167700 - Drug Profile 174
Recombinant Protein for Osteoarthritis - Drug Profile 176
Recombinant Protein to Agonize ALK and BMP Receptors for Alport Syndrome, Kidney Diseases, Metabolic Disorders and Osteoarthritis - Drug Profile 177
Recombinant Protein to Agonize IGF-1 Receptor for Osteoarthritis - Drug Profile 179
Recombinant Protein to Agonize IL-4 and IL-10 Receptors for Osteoarthritis and CNS - Drug Profile 180
Reg-O3 - Drug Profile 181
ReJoin - Drug Profile 182
salmon calcitonin - Drug Profile 186
SBL-005 - Drug Profile 188
SFX-01 - Drug Profile 189
SI-613 - Drug Profile 192
SM-04690 - Drug Profile 193
Small Molecule for Degenerative Arthritis - Drug Profile 196
Small Molecule for Osteoarthritis - Drug Profile 197
Small Molecule for Osteoarthritis - Drug Profile 198
Small Molecule for Osteoarthritis - Drug Profile 199
Small Molecule to Agonize A2A for Immunology, Hematological and Neurological Disorders - Drug Profile 200
Small Molecule to Target GPR22 for Anxiety, Cardiovascular Diseases and Osteoarthritis - Drug Profile 201
Small Molecules for Metabolic and Musculoskeletal Disorders - Drug Profile 202
Small Molecules for Musculoskeletal and Metabolic Disorders - Drug Profile 203
Small Molecules for Osteoarthritis - Drug Profile 204
Small Molecules for Osteoarthritis - Drug Profile 205
Small Molecules to Inhibit ADAMTS-5 for Osteoarthritis - Drug Profile 206
Small Molecules to Inhibit iNOS for Osteoarthritis - Drug Profile 207
Small Molecules to Inhibit MMP-13 for Osteoarthritis - Drug Profile 208
sprifermin - Drug Profile 209
Stem Cell Therapy for Articular Cartilage Lesions and Osteoarthritis - Drug Profile 211
Stem Cell Therapy for Autoimmune Diseases - Drug Profile 212
Stem Cell Therapy for CNS Disorders, Rheumatoid Arthritis, Osteoarthritis, Bronchopulmonary Dysplasia and Heart Failure - Drug Profile 214
Stem Cell Therapy for Diabetes Mellitus, Acute Liver Failure, Osteoarthritis and Neurodegenerative Diseases - Drug Profile 215
Stem Cell Therapy for Osteoarthritis and Rheumatoid Arthritis - Drug Profile 216
Stem Cell Therapy for Osteoarthritis, Atherosclerosis and Arteriosclerosis Obliterans - Drug Profile 217
Stempeucel - Drug Profile 218
tonogenchoncel-L - Drug Profile 221
TPX-100 - Drug Profile 224
TRBN-0224 - Drug Profile 226
UGP-302 - Drug Profile 228
VA-694 - Drug Profile 230
X-0002 - Drug Profile 231
XT-101 - Drug Profile 233
XT-150 - Drug Profile 234
YH-14619 - Drug Profile 235
YRA-1909 - Drug Profile 236
YY-1201 - Drug Profile 237
YYD-302 - Drug Profile 238
Osteoarthritis - Dormant Projects 239
Osteoarthritis - Discontinued Products 246
Osteoarthritis - Product Development Milestones 248
Featured News & Press Releases 248
Appendix 261
Methodology 261
Coverage 261
Secondary Research 261
Primary Research 261
Expert Panel Validation 261
Contact Us 261
Disclaimer 262

List of Tables

Number of Products under Development for Osteoarthritis, H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..2), H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..3), H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..4), H1 2017
Number of Products under Development by Universities/Institutes, H1 2017
Products under Development by Companies, H1 2017
Products under Development by Companies, H1 2017 (Contd..1), H1 2017
Products under Development by Companies, H1 2017 (Contd..2), H1 2017
Products under Development by Companies, H1 2017 (Contd..3), H1 2017
Products under Development by Companies, H1 2017 (Contd..4), H1 2017
Products under Development by Companies, H1 2017 (Contd..5), H1 2017
Products under Development by Universities/Institutes, H1 2017
Number of Products by Stage and Target, H1 2017
Number of Products by Stage and Target, H1 2017 (Contd..1), H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1), H1 2017
Number of Products by Stage and Route of Administration, H1 2017
Number of Products by Stage and Molecule Type, H1 2017
Osteoarthritis - Pipeline by A. Menarini Industrie Farmaceutiche Riunite Srl, H1 2017
Osteoarthritis - Pipeline by AbbVie Inc, H1 2017
Osteoarthritis - Pipeline by Abiogen Pharma SpA, H1 2017
Osteoarthritis - Pipeline by Ablynx NV, H1 2017
Osteoarthritis - Pipeline by Achelios Therapeutics Inc, H1 2017
Osteoarthritis - Pipeline by Addex Therapeutics Ltd, H1 2017
Osteoarthritis - Pipeline by Amgen Inc, H1 2017
Osteoarthritis - Pipeline by Amura Holdings Ltd, H1 2017
Osteoarthritis - Pipeline by Arcarios BV, H1 2017
Osteoarthritis - Pipeline by Asahi Kasei Pharma Corp, H1 2017
Osteoarthritis - Pipeline by Asklepios BioPharmaceutical Inc, H1 2017
Osteoarthritis - Pipeline by Astellas Pharma Inc, H1 2017
Osteoarthritis - Pipeline by Biopharm GmbH, H1 2017
Osteoarthritis - Pipeline by Bone Therapeutics SA, H1 2017
Osteoarthritis - Pipeline by Can-Fite BioPharma Ltd, H1 2017
Osteoarthritis - Pipeline by Cardax Inc, H1 2017
Osteoarthritis - Pipeline by Cellular Biomedicine Group Inc, H1 2017
Osteoarthritis - Pipeline by Cipla Ltd, H1 2017
Osteoarthritis - Pipeline by Corestem Inc, H1 2017
Osteoarthritis - Pipeline by Dong-A Socio Holdings Co Ltd, H1 2017
Osteoarthritis - Pipeline by Evgen Pharma Plc, H1 2017
Osteoarthritis - Pipeline by F. Hoffmann-La Roche Ltd, H1 2017
Osteoarthritis - Pipeline by Galapagos NV, H1 2017
Osteoarthritis - Pipeline by Gemphire Therapeutics Inc, H1 2017
Osteoarthritis - Pipeline by GeneFrontier Corp, H1 2017
Osteoarthritis - Pipeline by Genequine Biotherapeutics GmbH, H1 2017
Osteoarthritis - Pipeline by GlaxoSmithKline Plc, H1 2017
Osteoarthritis - Pipeline by HSRx Group, H1 2017
Osteoarthritis - Pipeline by InKemia IUCT Group SA, H1 2017
Osteoarthritis - Pipeline by International Stem Cell Corp, H1 2017
Osteoarthritis - Pipeline by Jeil Pharmaceutical Co Ltd, H1 2017
Osteoarthritis - Pipeline by Jenrin Discovery Inc, H1 2017
Osteoarthritis - Pipeline by K-Stemcell Co Ltd, H1 2017
Osteoarthritis - Pipeline by Kang Stem Biotech Co Ltd, H1 2017
Osteoarthritis - Pipeline by Levolta Pharmaceuticals Inc, H1 2017
Osteoarthritis - Pipeline by LG Chem, Ltd., H1 2017
Osteoarthritis - Pipeline by Marina Biotech Inc, H1 2017
Osteoarthritis - Pipeline by Medivir AB, H1 2017
Osteoarthritis - Pipeline by Merck KGaA, H1 2017
Osteoarthritis - Pipeline by Mesoblast Ltd, H1 2017
Osteoarthritis - Pipeline by Mor Research Application Ltd, H1 2017
Osteoarthritis - Pipeline by NicOx SA, H1 2017
Osteoarthritis - Pipeline by Nordic Bioscience A/S, H1 2017
Osteoarthritis - Pipeline by Novartis AG, H1 2017
Osteoarthritis - Pipeline by NovelMed Therapeutics Inc, H1 2017
Osteoarthritis - Pipeline by Omeros Corp, H1 2017
Osteoarthritis - Pipeline by Ono Pharmaceutical Co Ltd, H1 2017
Osteoarthritis - Pipeline by OrthoCyte Corp, H1 2017
Osteoarthritis - Pipeline by Osteologix Holdings Plc, H1 2017
Osteoarthritis - Pipeline by Pfizer Inc, H1 2017
Osteoarthritis - Pipeline by Pharmalink AB, H1 2017
Osteoarthritis - Pipeline by Philogen SpA, H1 2017
Osteoarthritis - Pipeline by PhytoHealth Corp, H1 2017
Osteoarthritis - Pipeline by PLx Pharma Inc, H1 2017
Osteoarthritis - Pipeline by ProteoThera Inc, H1 2017
Osteoarthritis - Pipeline by Regeneus Ltd, H1 2017
Osteoarthritis - Pipeline by Regulaxis SAS, H1 2017
Osteoarthritis - Pipeline by Rottapharm Biotech Srl, H1 2017
Osteoarthritis - Pipeline by Samumed LLC, H1 2017
Osteoarthritis - Pipeline by Seikagaku Corp, H1 2017
Osteoarthritis - Pipeline by Stelis Biopharma Pvt Ltd, H1 2017
Osteoarthritis - Pipeline by Takeda Pharmaceutical Company Ltd, H1 2017
Osteoarthritis - Pipeline by TissueGene Inc, H1 2017
Osteoarthritis - Pipeline by Yooyoung Pharmaceutical Co Ltd, H1 2017
Osteoarthritis - Pipeline by Yuhan Corp, H1 2017
Osteoarthritis - Pipeline by Yungjin Pharm Co Ltd, H1 2017
Osteoarthritis - Pipeline by Zimmer Biomet Holdings Inc, H1 2017
Osteoarthritis - Dormant Projects, H1 2017
Osteoarthritis - Dormant Projects, H1 2017 (Contd..1), H1 2017
Osteoarthritis - Dormant Projects, H1 2017 (Contd..2), H1 2017
Osteoarthritis - Dormant Projects, H1 2017 (Contd..3), H1 2017
Osteoarthritis - Dormant Projects, H1 2017 (Contd..4), H1 2017
Osteoarthritis - Dormant Projects, H1 2017 (Contd..5), H1 2017
Osteoarthritis - Discontinued Products, H1 2017
Osteoarthritis - Discontinued Products, H1 2017 (Contd..1), H1 2017